Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SABS
SABS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SABS News
Rare Hantavirus Outbreak Sparks Market Response
10h ago
stocktwits
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
Apr 29 2026
Globenewswire
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
Apr 29 2026
Newsfilter
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Apr 22 2026
moomoo
SAB Biotherapeutics Completes $85M Stock Offering
Mar 18 2026
seekingalpha
SAB Biotherapeutics Launches Public Offering to Fund Diabetes Candidate
Mar 17 2026
seekingalpha
SAB Biotherapeutics Reports Positive Phase 1 Data for SAB-142 in T1D
Mar 10 2026
Newsfilter
SAB Biotherapeutics Reports 2025 Financial Highlights
Mar 09 2026
seekingalpha
SAB Biotherapeutics Advances SAB-142 into Phase 2b Clinical Study
Mar 09 2026
Newsfilter
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
Mar 01 2026
Yahoo Finance
SAB Biotherapeutics Advances SAB-142 Clinical Trial for Stage 3 Diabetes Treatment Following Positive Phase 1 Results
Dec 17 2025
Globenewswire
SAB Biotherapeutics Confirms SAB-142 Safety, Advances to Phase 2b Clinical Trial
Dec 17 2025
Newsfilter
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Nov 13 2025
Newsfilter
SAB BIO Showcases Data Through Various Presentations at EASD
Sep 19 2025
Newsfilter
Leerink Partners Begins Coverage of SAB Biotherapeutics (SABS) with a Positive Outlook
Sep 18 2025
NASDAQ.COM
Leerink Partners Begins Coverage of SAB Biotherapeutics with Outperform Rating and Sets Price Target at $7
Sep 17 2025
Benzinga
Show More News
